Greensboro, NC, United States of America

Imogene M Dunn

USPTO Granted Patents = 1 

Average Co-Inventor Count = 5.0

ph-index = 1

Forward Citations = 5(Granted Patents)


Company Filing History:


Years Active: 2017

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Imogene M Dunn: Innovator in Alzheimer's Treatment

Introduction

Imogene M Dunn is a notable inventor based in Greensboro, NC (US). She has made significant contributions to the field of pharmaceuticals, particularly in the treatment of Alzheimer's disease. Her innovative approach has led to the development of a unique compound aimed at addressing various health issues.

Latest Patents

Imogene holds 1 patent for her invention titled "Treatment of mild and moderate Alzheimer's disease." This patent relates to methods of treatment using [3-(4-{2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1H-imidazol-4-yl}-phenoxy)-propyl]-diethyl amine, referred to as 'COMPOUND I.' The invention encompasses treatment methods for mild-to-moderate dementia of Alzheimer's type, diabetes, insomnia, and other indications. Additionally, it includes pharmaceutical compositions comprising COMPOUND I or its pharmaceutically acceptable salts.

Career Highlights

Imogene M Dunn has established herself as a key figure in the pharmaceutical industry. Her work at Vtv Therapeutics LLC has been instrumental in advancing treatments for neurodegenerative diseases. Her dedication to research and innovation has positioned her as a leader in her field.

Collaborations

Imogene has collaborated with esteemed colleagues such as Cesare Orlandi and David J Clark. These partnerships have enhanced her research efforts and contributed to the development of effective treatment methodologies.

Conclusion

Imogene M Dunn's contributions to the treatment of Alzheimer's disease exemplify her commitment to innovation in healthcare. Her work continues to inspire advancements in pharmaceutical research and development.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…